The official journal of the Brazilian Retina and Vitreous Society
A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD).